FindTrial
Sign In

A Prospective Study to Determine the Optimal Volume of Ascitic Fluid Required to Confirm Malignant Ascitic Fluid in 123 Patients with Shifting Dullness

A Prospective Study to Determine the Optimal Volume of Ascitic Fluid Required to Confirm Malignant Ascitic Fluid in 123 Patients with Shifting Dullness

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17010959
Enrollment
Unknown
Registered
2017-03-23
Start date
2017-03-22
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant ascitic fluid

Interventions

Gold Standard:finding tumor cells in ascitic fluid
Index test:malignant cells

Sponsors

Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with confirmed or suspected malignanct ascitic fluid

Exclusion criteria

Exclusion criteria: without shifting dullness

Design outcomes

Primary

MeasureTime frame
malignant cells;—

Countries

China

Contacts

Public ContactJin Shizhu

Department of Gastroenterology and Hepatology, the Second Affiliated Hospital of Harbin Medical University

drshizhujinsci@126.com+86 13654699988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026